DGAP-News: Epigenomics AG / Key word(s): Annual Report/Annual Results24.03.2022 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for Fiscal Year 2021 Total revenue of EUR 6.2 million, adjusted EBITDA of EUR -1.8 million FDA clinical trial for Epi proColon “Next Gen” expected to start with […]
Year: 2022
26. January 2022
Epigenomics AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
Epigenomics AG26.01.2022 / 10:12 Veröffentlichung einer Stimmrechtsmitteilung übermittelt durch DGAP – ein Service der EQS Group AG.Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Stimmrechtsmitteilung 1. Angaben zum Emittenten Name: Epigenomics AG Straße, Hausnr.: Geneststraße 5 PLZ: 10829 Ort: BerlinDeutschland Legal Entity Identifier (LEI): 549300X1C4U862NDLN97 2. Grund der Mitteilung Erwerb bzw. […]
24. January 2022
Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Epigenomics AG / Total Voting Rights Announcement 24.01.2022 / 11:39 Total Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of total number of voting rights1. Details of issuer Epigenomics AG Geneststraße 5 10829 Berlin Germany 2. Type of […]
24. January 2022
Supervisory Board of Epigenomics AG Retains Greg Hamilton as Chief Executive Officer Through Development of Epi proColon ‘Next-Gen’ Colorectal Cancer Screening Test
DGAP-News: Epigenomics AG / Key word(s): Personnel24.01.2022 / 07:00 The issuer is solely responsible for the content of this announcement. Supervisory Board of Epigenomics AG Retains Greg Hamilton as Chief Executive Officer Through Development of Epi proColon “Next-Gen” Colorectal Cancer Screening Test Greg Hamilton retained as CEO through 2025 Appointment underscores Epigenomics’ commitment to the […]
21. January 2022
Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Epigenomics AG21.01.2022 / 11:30 Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Epigenomics AG Street: Geneststraße 5 Postal code: 10829 City: BerlinGermany Legal Entity Identifier (LEI): 549300X1C4U862NDLN97 2. […]